Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 2/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806939 | 0.84 | PIM3 (0.51) | PIM3PIM2ADORA2AADORA2BL3MBTL1 | |
| SCHEMBL1520260 | 0.78 | MAPT (0.60) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL13283350 | 0.76 | PIM3 (0.57) | PIM3PIM2ADORA2AADORA2BSMN1; SMN2 | |
| SCHEMBL6930385 | 0.74 | PIM3 (0.46) | PIM3PIM2ADORA2AADORA2BL3MBTL1 | |
| SCHEMBL1520694 | 0.71 | PIM3 (0.74) | PIM3PIM2L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL20239461 | 0.71 | PIM3 (0.74) | PIM3PIM2L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL12733934 | 0.70 | PIM3 (0.51) | PIM3PIM2ADORA2AADORA2BL3MBTL1 | |
| SCHEMBL13255847 | 0.70 | PIM3 (0.51) | PIM3PIM2ADORA2AADORA2BL3MBTL1 | |
| SCHEMBL27794953 | 0.70 | PIM3 (0.51) | PIM3PIM2ADORA2AADORA2BL3MBTL1 | |
| SCHEMBL1043176 | 0.70 | PIM3 (0.72) | PIM3PIM2L3MBTL1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| CN-101842357-A | Substituted pyrazole derivatives | TAKEDA PHARMACEUTICAL | 2010-09-22 | — | — | CN | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | PIM3 749/4885PIM2 1120/4885ADORA2A 1159/4885 |
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | PIM3 1115/4885PIM2 1036/4885ADORA2A 616/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PIM3 4213/4885PIM2 4457/4885ADORA2A 680/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | PIM3 762/4885PIM2 1132/4885ADORA2A 1110/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | PIM3 1392/4885PIM2 1230/4885ADORA2A 515/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PIM3 4213/4885PIM2 4457/4885ADORA2A 680/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PIM3 4213/4885PIM2 4457/4885ADORA2A 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.